ClinicaliQ Trial Snapshot
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Active Not Recruiting • Phase III • NCT06331312.
- Long-term safety study of secukinumab (an IL-17 inhibitor) in patients with polymyalgia rheumatica to assess tolerability and adverse effects.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. Conditions: Polymyalgia Rheumatica Interventions: Secukinumab Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 162 participants